| Authors: |
Fontana M; National Amyloidosis Centre, UCL, Division of Medicine, University College London, Royal Free Hospital, Pond Street, London, NW3 2QG, UK. marianna.fontana@nhs.net., Algalarrondo V; French Reference Centre for Cardiac Amyloidosis Ceramic-Cardio, Department of Cardiology, Bichat University Hospital, AP-HP, Paris, France., Garcia-Pavia P; Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Maurer MS; Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA., Gillmore JD; National Amyloidosis Centre, UCL, Division of Medicine, University College London, Royal Free Hospital, Pond Street, London, NW3 2QG, UK., Cappelli F; Tuscan Regional Amyloidosis Centre and Cardiomyopathy Unit, Careggi University Hospital, University of Florence, Florence, Italy., Kolachana K; Alnylam Pharmaceuticals, Cambridge, MA, USA., Gao X; Alnylam Pharmaceuticals, Cambridge, MA, USA., Jadhav S; Alnylam Pharmaceuticals, Cambridge, MA, USA., Mehrotra N; Alnylam Pharmaceuticals, Cambridge, MA, USA., Robbie G; Alnylam Pharmaceuticals, Cambridge, MA, USA., Badri P; Alnylam Pharmaceuticals, Cambridge, MA, USA. |
